Clinical trials: Sintilimab
Relapsed or Refractory Classical Hodgkin's Lymphoma
Intense Monitoring Study on Tyvyt
The study is a multi-center, prospective, non-interventional and observational study, and will collect data on the safety and efficacy of Tyvyt® in the treatment of Chinese patients with relapsed or refractory classical Hodgkin's…
- Trial name
- NCT04237233
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Classical Hodgkin Lymphoma
Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study
Study Purpose: To evaluate the efficacy and safety of sintilimab in combination with AVD chemotherapy for the treatment of pediatric and adolescent patients with low-to-intermediate risk classical Hodgkin lymphoma (cHL).
- Trial name
- NCT06848569
- Testing
- Sintilimab in combination with AVD chemotherapy
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Sun Yat-sen University
Soft Tissue Sarcoma
Adriamycin and Ifosfamide Combined With Sintilimab
The aim of this study was to explore the efficacy and safety of adriamycin and ifosfamide combined with sintilimab versus chemotherapy in the treatment of advanced or unresectable soft tissue sarcoma.
- Trial name
- NCT04589754
- Testing
- Sintilimab plus chemotherapy, Adriamycin-based chemotherapy
- Where
- China
- Volunteers
- 176 people
- Sponsor
- Sun Yat-sen University
Neuroblastoma
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
This is an prospective study to evaluate the safety and efficacy of naxitamab monotherapy or combined with chemotherapy or combined with chemotherapy and checkpoint inhibitor in the treatment of pediatric high-risk and…
- Trial name
- NCT06013618
- Testing
- Naxitamab monotherapy, GM-CSF, Irinotecan
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-Sen University Cancer Center
Huge Hepatocellular Carcinoma (HCC) (>10cm)
The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Period of Huge Hepatocellular Carcinoma: A Retrospective Cohort Study
This retrospective cohort study collected data of patients with huge hepatocellular carcinoma (HCC) treated between June 1, 2018, and December 31, 2023, through the hospital information system.
- Trial name
- NCT07639294
- Testing
- hepatectomy without immune checkpoint inhibitors-based adjuvant therapy, hepatectomy with immune checkpoint inhibitors-based adjuvant therapy, neoadjuvant conversion therapy followed by surgery
- Where
- China
- Volunteers
- 715 people
- Sponsor
- Tongji Hospital
Gastric Cancer (Diagnosis)
A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy
To explore the efficacy and safety of sintilimab combined with ramucirumab and paclitaxel in the treatment of advanced gastric cancer patients with short-term recurrence after postoperative adjuvant therapy, and to identify…
- Trial name
- NCT07669740
- Testing
- Sintilimab Combined with Ramucirumab and Paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Solid Tumors, Lung Adenocarcinoma
IBI188 Combination Therapy in Solid Tumors
A Phase Ib study aim to evaluate the efficacy, safety, and tolerability of IBI188 combination therapy in subjects with advanced malignancies
- Conditions
- Solid Tumors, Lung Adenocarcinoma, Osteosarcoma
- Trial name
- NCT04861948
- Testing
- IBI188, GM-CSF, Cisplatin/Carboplatin
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Transitional Cell Tumor, Hepatoblastoma
Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy
This is a single arm, open-label trial studying the combination of PD-1/PD-L1 Inhibitor (e.g.pembrolizumab, Sintilimab,Duvarizumab，Camrelizumab )and lenvatinib given at the recommended dose in pediatric and young adolescent…
- Conditions
- Transitional Cell Tumor, Hepatoblastoma, Liver Cancer, Pediatric Solid Tumor
- Trial name
- sPLENTY-pc (NCT05322187)
- Testing
- PD-1 inhibitor
- Where
- China
- Volunteers
- 15 people
- Sponsor
- RenJi Hospital
Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma
Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
This study aims to evaluate the effectiveness and safety of a preoperative treatment (called neoadjuvant therapy) combining four drugs-nab-paclitaxel, oxaliplatin, S-1, and sintilimab-for patients with locally advanced…
- Conditions
- Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma, Locally Advanced
- Trial name
- YOUNG-NEOS (NCT07018063)
- Testing
- nab-paclitaxel, oxaliplatin, S-1
- Where
- China
- Volunteers
- 35 people
- Sponsor
- zhoujing
Liver Cancer
A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold Regions
Hepatocellular carcinoma (HCC) is a common global malignancy. In China, the disease burden is substantial: HCC ranks fifth in cancer incidence and third in mortality, with a 5-year relative survival of only 14.4%.
- Trial name
- NCT07645209
- Testing
- Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Harbin Medical University
Recurrent Stage IV High Risk Neuroblastoma
Study on Sintilimab in Stage IV High Risk Neuroblastoma
A phase I observational study on the safety and efficacy of treatment of recurrent stage IV high risk neuroblastoma with Nivolumab
- Trial name
- SCMC-S-2020 (NCT04412408)
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Children's Medical Center
Renal Cell Carcinoma (Kidney Cancer), Immunotherapy
Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial
This phase II, multicenter, single-arm, open-label study evaluates first-line ipilimumab N01 plus sintilimab and lenvatinib in patients with locally advanced or metastatic TFE3-rearranged renal cell carcinoma (TFE3-rRCC), a rare…
- Conditions
- Renal Cell Carcinoma (Kidney Cancer), Immunotherapy, Molecular Targeted Therapy
- Trial name
- NCT07715565
- Testing
- Ipilimumab Injection, Sintilimab injection, Lenvatinib
- Where
- China
- Volunteers
- 66 people
- Sponsor
- West China Hospital
Gastric Cancer
A Benefit Population Atlas of nICT Versus nCT for LAGC
The purpose of this observational study is to evaluate the impact of different neoadjuvant therapies on patients with locally advanced gastric cancer.
- Trial name
- NCT07098104
- Testing
- Immunotherapy
- Where
- China
- Volunteers
- 291 people
- Sponsor
- Cheng Chen
Colorectal Neoplasms, RAS
The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer
Colorectal cancer is a malignant tumor ranking among the top four in incidence and the top three in causes of death globally . Chemotherapy combined with anti-EGFR or anti-VEGF monoclonal antibodies is currently the standard…
- Conditions
- Colorectal Neoplasms, RAS, BRAF, Cetuximabβ
- Trial name
- concept (NCT07257653)
- Testing
- Cetuximab β；Fruquintinib；, Cetuximab β；Fruquintinib；anti-PD1 antibody；, Cetuximab β；Fruquintinib；anti-PD1/CTLA4 antibody
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Zhejiang University
Pediatric Cancer
Sintilimab in the Treatment of Advanced and Refractory Pediatric Malignant Tumors
This is a single center, single arm, open-label and phase I clinical study. The standard 3 + 3 group design was performed. Patients were enrolled by the design of phase I study standard.
- Trial name
- NCT04400851
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Sun Yat-sen University